188宝金博页面版

Br J Haematol. 2025;00:1–33. | 1 wileyonlinelibrary.com/journal/bjhG U I DE L I N EB S H G u i d e l i n eManagement of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guidelineMatthew Jenner 1 | Kevin Boyd 2 | Satarupa Choudhuri 3 | Christopher Parrish 4 | Mamta Garg 5 | Simon Stern 6 | on behalf of the British Society of Haematology and UK Myeloma Society1 University Hospital Southampton NHS Foundation Trust, Southampton, UK2 Royal Marsden Hospital NHS Foundation Trust, London, UK3 The Northern Care Alliance NHS Trust, Oldham, UK4 Leeds Teaching Hospitals NHS Trust, Leeds, UK5 University Hospitals of Leicester NHS Trust, Leicester, UK6 Epsom and St Helier University Hospitals NHS Trust, Surrey, UKCorrespondenceBSH Guidelines Administrator, British Society for Haematology, 100 White Lion Street, London N1 9PF, UK.Email: bshguidelines@b-s-h.org.ukKEYWORDSguidelines, management, relapsed multiple myelomaSCOPEThe objective of this guideline is to provide healthcare professionals with clear guidance on the management of patients with relapsed and refractory multiple myeloma who have disease progression after at least one prior ther-apy. These guidelines and recommendations do not re-place multidisciplinary discussion and the need to take account of clinical features, patient preference and the funding and reimbursement of treatments at any given point in time.METHODOLOGYThis guideline was compiled according to the British Society for Haematology (BSH) process at www. b- s- h. org. uk/ guide lines . The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate the levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at http:// www. grade worki nggro up. org and are summarised in appendix 3 of the guidance document linked above.Received: 25 July 2024 | Accepted: 2 September 2025DOI: 10.1111/bjh.70149 © 2025 British Society for Haematology and John Wiley & Sons Ltd.Abbreviations: Bela- PD, belanatmab pomalidomide dexamethasone; Bela- VD, belantamab bortezomib dexamethasone; Belamaf, belantamab mafodotin; Benda RD, bendamustine lenalidomide dexamethasone; Benda TD, bendamustine thalidomide dexamethasone; Benda VD, bendamustine velcade dexamethasone; CEVAD, cyclophosphamide, etoposide, vincristine, adriamycin, dexamethasone; Cilta- cel, ciltacabtagene autoleucel; CPD, cyclophosphamide, pomalidomide, dexamethasone; CRD, cyclophosphamide, lenalidomide, dexamethasone; CTD, cyclophosphamide, thalidomide, dexamethasone; CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone; CVD, cyclophosphamide, bortezomib, dexamethasone; Dara, daratumumab; Dara- KD, daratumumab, carfilzomib, dexamethasone; Dara- PD, daratumumab, pomalidomide, dexamethasone; Dara- RD, daratumumab, lenalidomide, dexamethasone; Dara- VD, daratumumab, bortezomib, dexamethasone; DCEP, dexamethasone, cyclophosphamide, etoposide, cisplatin; DT- PACE, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide ± thalidomide; Elo- PD, Elotuzumab, pomalidomide, dexamethasone; Elo- RD, Elotuzumab, lenalidomide, dexamethasone; ESHAP, Etoposide, methylprednisolone, cytarabine and cisplatin; Ide- cel, Idecabtagene vicleucel; Isatux- KD, Isatuximab, carfilzomib, dexamethasone; Isatux- PD, Isatuximab, pomalidomide, dexamethasone; Ixa- CD, Ixazomib, cyclophosphamide, dexamethasone; Ixa- RD, Ixazomib, lenalidomide, dexamethasone; KCD, carfilzomib, cyclophosphamide, dexamethasone; KD, carfilzomib, dexamethasone; KRD, carfilzomib, lenalidomide, dexamethasone; MPT, melphalan, prednisolone, thalidomide; OPP- EBV- CAD, vincristine, procarbazine, prednisone, epidoxirubicin, bleomycin, vinblastine, lomustine, doxorubicin, and vindesine; Pano- VD, panobinostat, bortezomib, dexamethasone; Pano- VTD, panobinostat bortezomib thalidomide dexamethasone; PD, pomalidomide, dexamethasone; PVD, pomalidomide, bortezomib, dexamethasone; RD, lenalidomide, dexamethasone; T or Thal, Thalidomide; TD, Thalidomide, dexamethasone; V, bortezomib; VD, bortezomib, dexamethasone; VMP, bortezomib, melphalan, prednisolone; Vori- VD, voriconazole bortezomib dexamethasone; VTD, bortezomib thalidomide dexamethasone; VTD- PACE, bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide.